The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer

Published:2024-06-19 Issue: Volume: Page:
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Le Guevelou Jennifer^ORCID,Cuccia Francesco,Flippot Ronan,Ferrera Giuseppe,Terlizzi Mario,Zilli Thomas^ORCID,De Crevoisier Renaud,Hannoun-Levi Jean-Michel,Supiot Stephane,Sargos Paul,Pasquier David^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41391-024-00862-8.pdf

Reference54 articles.

1. Dutt SS, Gao AC. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol. 2009;5:1403–13.

2. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79:150–8.

3. Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382:2197–206.

4. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383:1040–9.

5. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60.